Söndag 24 November | 15:34:07 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-08-21 08:30 Kvartalsrapport 2025-Q2
2025-04-30 08:30 Kvartalsrapport 2025-Q1
2025-02-13 08:30 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-04-30 - Kvartalsrapport 2024-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
NanoEcho är verksamt inom sjukvården, med huvudsaklig fokus inom rektalcancerdiagnostik. Bolaget är verksamt i kliniskt skede, där man utvecklar en ny diagnostisk metod för att fastställa om tidig rektalcancer har spridit sig till närliggande lymfkörtlar. Metoden ämnar ge en korrekt diagnos och individanpassad behandling. NanoEcho grundades år 2013 och har sitt huvudkontor i Lund.
2024-04-11 12:00:00

NanoEcho has, in collaboration with health economic experts, developed a model for health economic analysis of the introduction of NanoEcho's method in healthcare, with the aim of investigating the potential cost-effectiveness. The health economic model shows that the introduction of NanoEcho's diagnostic method has the potential to generate health economic gains. This analysis will form an important basis for NanoEcho's pricing strategy in the upcoming market launch.

The Institute for Healthcare Economics (IHE) has developed a health economic analysis to support decision-making in healthcare regarding the introduction of NanoEcho's diagnostic method. The goal of NanoEcho's method is to reliably map any rectal cancer spread to nearby lymph nodes.

The work with the model began with a basic mapping of clinical data, health effects and costs related to today's rectal cancer diagnostics. In the next step, IHE developed a health economic model to analyse the cost-effectiveness and budget impact of introducing NanoEcho's diagnostic method. The model is a powerful analysis tool to assess how the introduction of NanoEcho's diagnostic method affects healthcare costs, as well as how the introduction of the method has the potential to generate health gains in the form of patient benefits.

The health economic model shows that the introduction of NanoEcho's diagnostic method has the potential to generate health economic gains through cost savings in the form of reduced need for major operations, reduced overtreatment of early rectal cancer, and increased quality of life for patients with early rectal cancer.

"It has been a privilege to work together with IHE's health economics experts, who developed this important, powerful tool for us based on science. The health economic model not only gives us insights into the cost-effectiveness of introducing our diagnostic method, but also forms the basis for our pricing strategy for our upcoming market launch," says Linda Persson CEO of NanoEcho.